CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia

Trial Details

NCT ID

NCT02443831

Phase

PHASE1

Sponsor

University College, London

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

• Leukapheresis
• Total Body Irradiation (TBI)
• Lymphodepletion with Fludarabine
• Lymphodepletion with Cyclophosphamide
• CD19+CD22 CAR T-cells

Locations (sample)

• London, United Kingdom|51.50853,-0.12574
• London, United Kingdom|51.50853,-0.12574
• Manchester, United Kingdom|53.48095,-2.23743

Key Eligibility Criteria

• Children and young adults (age 24 years or younger) with high risk/relapsed CD19+ and CD22+ acute lymphoblastic leukaemia with:
• Resistant disease (\>5% blasts) at end of ALLTogether-1 protocol or equivalent induction
• ALL with persisting high level MRD at 2nd time point of frontline national protocol (currently MRD \>10-4 at week 9 ALLTogether-1 Protocol or equiv…
• High risk infant ALL (age \< 6 months at diagnosis with MLL gene rearrangement and either presenting white cell count \> 300 x 10\^9/L or poor ster…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.